SEP 06, 2015 02:29 PM PDT

Aspirin and Cancer

Immunotherapy is powerful, and British researchers have found a way to make it even more so. By giving cancer patients aspirin at the same time as they receive immunotherapy, clinicians can dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell and reported in Drug Discovery & Development
Aspirin boosts effects of chemotherapy. 
Funded by Cancer Research UK, a group of researchers at the Francis Crick Institute demonstrated that skin, breast and bowel cancer cells often produce large amounts of prostaglandin E2 (PGE2). This molecule interferes with the immune system's usual response to attack faulty cells, which enables cancer to hide. “It is a trick that allows the tumor to thrive and may explain why some immunotherapy treatments have not been as effective as hoped,” according to Cancer Research UK.
 
Aspirin, which is part of a group of molecules called COX inhibitors, can halt the production of PGE2 and assist in reawakening the immune system. By combining immunotherapy with aspirin or other COX inhibitors, the researchers could significantly slow down bowel and melanoma skin cancer growth in mice, as compared to immunotherapy alone.
 
According to one of the study authors, Professor Caetano Reis e Sousa, who is senior group leader at the Francis Crick Institute, "We've added to the growing evidence that some cancers produce PGE2 as a way of escaping the immune system. If you can take away cancer cells' ability to make PGE2, you effectively lift this protective barrier and unleash the full power of the immune system. Giving patients COX inhibitors like aspirin at the same time as immunotherapy could potentially make a huge difference to the benefit they get from treatment. It's still early work, but this could help make cancer immunotherapy even more effective, delivering life-changing results for patients."
 
As Professor Peter Johnson, Cancer Research UK's chief clinician, explained, "PGE2 acts on many different cells in our body, and this study suggests that one of these actions is to tell our immune system to ignore cancer cells. Once you stop the cancer cells from producing it, the immune system switches back to 'kill mode' and attacks the tumor. This research was carried out in mice, so there is still some way to go before we will see patients being given COX inhibitors as part of their treatment. But it's an exciting finding that could offer a simple way to dramatically improve the response to treatment in a range of cancers."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 05, 2018
Cancer
JUN 05, 2018
Clinical Trial Evaluates Precision Medicine Approaches for Common and Rare Cancers
The NCI-MATCH Phase II Clinical Trial is evaluating results of cancer treatments administered based on genetic profiles determined through molecular diagnostic testing....
JUN 05, 2018
Cell & Molecular Biology
JUN 05, 2018
Mechanism of Aspirin's Anti-Colon Cancer Effects Revealed
For some people, aspirin can help prevent colon cancer; now researchers have learned more about how that happens....
JUN 25, 2018
Cancer
JUN 25, 2018
B-cell Lymphoma Develops After MPN JAK1/2 Therapy
Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitor therapy are at increased risk of developing aggressive B-cell lymphoma due to pre-existing B-cell clone specifically a...
SEP 06, 2018
Microbiology
SEP 06, 2018
The Oncomicrobiome - Linking Microbes and Cancer
Scientists want to know more about how the microbes we carry in and on us are related to cancer development....
SEP 20, 2018
Genetics & Genomics
SEP 20, 2018
Liquid Phase Separation may Play a Role in Cancer
Not all liquids mix, like oil and water; the phenomenon is called liquid-liquid phase separation. We're learning more about its role in cells....
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
Loading Comments...